checkpoint inhibitors

White arrow on a road pointing to the rising sun
Biotech

Pfizer ties PD-1 drug to 32% cancer risk reduction in phase 3

The study fell short of a clean sweep, with Pfizer finding no effect on survival and seeing a higher rate of serious adverse events in the PD-1 arm.
Nick Paul Taylor Apr 28, 2025 7:25am
Hiker having trouble climbing mountain

ALX Oncology doubles down as lead asset fails 2 phase 2 trials

Apr 25, 2025 2:25pm
bouncing ball trajectory

Sanofi passes $125M ILT2 asset back to Biond Biologics

Mar 3, 2025 11:00am
Combine

Pfizer to test Summit's white-hot bispecific with ADCs

Feb 24, 2025 9:17am
Deal terminate tear up end deal scrap

Incyte exits cancer pact, leaving Agenus weighing its options

Feb 11, 2025 7:55am
Soccer ball flying into a net scoring a goal

Pfizer's PD-1 prospect hits goal in phase 3 bladder cancer study

Jan 10, 2025 6:45am